Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects : Evidence for Injection Interval of Up to 2 MonthsTROCONIZ, Inaki F; CENDROS, Josep-Maria; PERAIRE, Concepcion et al.Clinical pharmacokinetics. 2009, Vol 48, Num 1, pp 51-62, issn 0312-5963, 12 p.Article

Lanreotide in Metastatic Enteropancreatic Neuroendocrine TumorsCAPLIN, Martyn E; PAVEL, Marianne; RINDI, Guido et al.The New England journal of medicine. 2014, Vol 371, Num 3, pp 224-233, issn 0028-4793, 10 p.Article

Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteersDREWE, J; SIEBER, C. C; MOTTET, C et al.Clinical pharmacology and therapeutics. 1999, Vol 65, Num 4, pp 413-419, issn 0009-9236Article

Mésothéliome péritonéal : longue survie sous chimiothérapie intrapéritonéale, lanréotide et mucolytiques = Peritoneal mesothelioma : Long survival with intraperitoneal chemotherapy, lanreotide and mucolyticsMONTMAYEUR, Gaëlle; THIVAT, Emilie; GIMBERGUES, Pierre et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 10, pp 874-875, issn 0399-8320, 2 p.Article

The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LARASHWELL, S. G; BEVAN, J. S; EDWARDS, O. M et al.European journal of endocrinology. 2004, Vol 150, Num 4, pp 473-480, issn 0804-4643, 8 p.Article

Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegalyCARON, Philippe; COGNE, Muriel; RAINGEARD, Isabelle et al.Clinical endocrinology (Oxford. Print). 2006, Vol 64, Num 2, pp 209-214, issn 0300-0664, 6 p.Article

¹¹¹In- and ⁹⁰Y-DOTA-lanreotide: Results and implications of the MAURITIUS trialVIRGOLINI, Irene; BRITTON, Keith; BUSCOMBE, John et al.Seminars in nuclear medicine. 2002, Vol 32, Num 2, pp 148-155, issn 0001-2998Article

Lanreotide Autogel^®: A Review of its Use in the Treatment of Patients with AcromegalyBURNESS, Celeste B; DHILLON, Sohita; KEAM, Susan J et al.Drugs (Basel). 2014, Vol 74, Num 14, pp 1673-1691, issn 0012-6667, 19 p.Article

The long-term outcome of patients with polycystic liver disease treated with lanreotideCHRISPIJN, M; NEVENS, F; DRENTH, J. P. H et al.Alimentary pharmacology & therapeutics. 2012, Vol 35, Num 2, pp 266-274, issn 0269-2813, 9 p.Article

Lanreotide Autogel® : A Review of its Use in the Management of Acromegaly. CommentaryCROXTALL, Jamie D; SCOTT, Lesley J; MOLITCH, Mark E et al.Drugs (Basel). 2008, Vol 68, Num 5, pp 711-724, issn 0012-6667, 14 p.Article

Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotideBORBATH, Ivan; LECLERCQ, Isabelle A; ABARCA-QUINONES, Jorge et al.Cancer science. 2007, Vol 98, Num 12, pp 1831-1839, issn 1347-9032, 9 p.Article

Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancerBATTAGLIA, Michele; DITONNO, Pasquale; PALAZZO, Silvano et al.Scandinavian journal of urology and nephrology. 2006, Vol 40, Num 5, pp 423-425, issn 0036-5599, 3 p.Article

Radiopharmacokinetic and dosimetric parameters of ¹⁸⁸Re-lanreotide in athymic mice with induced human cancer tumorsMOLINA-TRINIDAD, Eva M; ARTEAGA DE MURPHY, Consuelo; FERRO-FLORES, Guillermina et al.International journal of pharmaceutics. 2006, Vol 310, Num 1-2, pp 125-130, issn 0378-5173, 6 p.Article

L'acromégalie et ses traitements = Acromegaly and treatmentLa Revue Prescrire. 2004, Vol 24, Num 252, pp 535-537, issn 0247-7750, 3 p.Article

Stratégies thérapeutiques des tumeurs endocrines pancréatiques : Affections pancréatiques = Treatment strategy for pancreatic endocrine tumours : Pancreatic diseasesMITRY, Emmanuel; ROUGIER, Philippe.Gastroentérologie clinique et biologique. 2003, Vol 27, Num 3, pp 1S31-1S36, issn 0399-8320, SUPArticle

Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosisSCHIEDERMAIER, P; KOCH, L; STOFFEL-WAGNER, B et al.Alimentary pharmacology & therapeutics. 2003, Vol 18, Num 8, pp 777-784, issn 0269-2813, 8 p.Article

A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patientsKOUTSILIERIS, Michael; MITSIADES, Constantine; DIMOPOULOS, Theodore et al.The Journal of clinical endocrinology and metabolism. 2001, Vol 86, Num 12, pp 5729-5736, issn 0021-972XArticle

Le lanréotide peut traiter une dystrophie kystique de la paroi duodénale développée sur pancréas aberrant : Tube digestif et pancréas = Lanreotide acetate may cure cystic dystrophy in heterotopic pancreas of the duodenal wall : Digestive tract and pancreasBASILI, Enrique; ALLEMAND, Isabelle; VILLE, Eric et al.Gastroentérologie clinique et biologique. 2001, Vol 25, Num 12, pp 1108-1111, issn 0399-8320Article

Treatment of neuroendocrine GEP tumours with somatostatin analogues: A reviewARNOLD, R; SIMON, B; WIED, M et al.Digestion. 2000, Vol 62, pp 84-91, issn 0012-2823, SUP1Conference Paper

Les agonistes de la somatostatine = Somatostatin agonistesBRUE, T; SAVEANU, A; VALLETTE-KASIC, S et al.MTE. Médecine thérapeutique endocrinologie. 2000, Vol 2, Num 2, pp 137-143, issn 1295-9359Article

Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiencyBARBANOJ, M; ANTONIJOAN, R; OBACH, R et al.Clinical pharmacology and therapeutics. 1999, Vol 66, Num 5, pp 485-491, issn 0009-9236Article

Effects of sustained-release lanreotide on hemodynamics in rats with portal vein stenosisLIN, H.-C; HUANG, Y.-T; WU, H.-L et al.Journal of hepatology. 1999, Vol 31, Num 3, pp 482-488, issn 0168-8278Article

EVALUATION DES EFFETS DES ANALOGUES DE LA SOMATOSTATINE AU NIVEAU DU TUBE DIGESTIF, EN SITUATIONS PHYSIOLOGIQUE ET PATHOLOGIQUE = EVALUATION THE EFFECTS OF SOMATOSTATIN ANALOGUES ON DIGESTIVE TRACT, IN PHYSIOLOGIC AND PATHOLOGIC SITUATIONSLamrani Ghaouti, Assia; Chaussade, Stanislas.1999, 266 p.Thesis

Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoidDRANGE, M. R; MELMED, S.The Journal of clinical endocrinology and metabolism. 1998, Vol 83, Num 9, pp 3104-3109, issn 0021-972XArticle

Indium-111-DOTA-lanreotide : Biodistribution, safety and radiation absorbed dose in tumor patientsVIRGOLINI, I; SZILVASI, I; KLETTER, K et al.The Journal of nuclear medicine (1978). 1998, Vol 39, Num 11, pp 1928-1936, issn 0161-5505Article